Northland Securities analyst Suraj Kalia maintained a Buy rating on Insulet Corp (NASDAQ: PODD) today and set a price target of $100. The company’s shares closed yesterday at $87.54.
According to TipRanks.com, Kalia is a 5-star analyst with an average return of 15.5% and a 61.8% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Obalon Therapeutics Inc, and Apollo Endosurgery Inc.
Currently, the analyst consensus on Insulet Corp is a Strong Buy with an average price target of $102.60, implying a 17.2% upside from current levels. In a report released today, Piper Jaffray also maintained a Buy rating on the stock with a $106 price target.
.
See today’s analyst top recommended stocks >>
Based on Insulet Corp’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $1.69 million. In comparison, last year the company had a GAAP net loss of $7.77 million.
Based on the recent corporate insider activity of 72 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Insulet Corp. is an innovative medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Billerica, MA.
